90Y-FAPi-46 is the therapeutic analogue of the PET Imaging agent 68Ga-FAPi-46 from the FAPi family developed at the Cancer Research Center of Heidelberg, Germany. It is a radiotherapeutic agent based on a Fibroblast Activation Protein (FAP)-specific enzyme inhibitor (FAPi), to be found on almost all solid tumors. The first clinical Dosimetry trial was performed at University Hospital Essen, Germany.
FAPis target cancer-associated fibroblasts (CAFs), yielding images with similar or better quality compared with 18F-FDG-PET/CT among patients with cancer and the 90Y-labeled analogue can find applications as therapeutics for these same patients. Besides cancer, FAPis may also be used for benign diseases such as fibroses, Atherosclerosis, rheumatoid arthritis, sarcoidosis, etc.
Radiation Type: beta electrons (β–)